New cancer drug candidate HLX18 faces off against OPDIVO® in early trial
NCT ID NCT07518043
First seen Apr 10, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This early-stage study tests whether a new drug, HLX18, works similarly to the approved cancer drug OPDIVO®. About 174 adults with esophageal cancer, melanoma, or bladder cancer who had surgery will receive either HLX18 or OPDIVO®. The goal is to compare how the drugs move through the body, their safety, and how well they prevent cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.